BR112017014225A2 - cultura biologicamente pura de lactobacillus reuteri, cepas lactobacillus reuteri, composição de uso de uma ou mais cepas de bactérias do ácido láctico, e da composição, e, método para administração tópica de cepas de bactérias do ácido láctico. - Google Patents

cultura biologicamente pura de lactobacillus reuteri, cepas lactobacillus reuteri, composição de uso de uma ou mais cepas de bactérias do ácido láctico, e da composição, e, método para administração tópica de cepas de bactérias do ácido láctico.

Info

Publication number
BR112017014225A2
BR112017014225A2 BR112017014225A BR112017014225A BR112017014225A2 BR 112017014225 A2 BR112017014225 A2 BR 112017014225A2 BR 112017014225 A BR112017014225 A BR 112017014225A BR 112017014225 A BR112017014225 A BR 112017014225A BR 112017014225 A2 BR112017014225 A2 BR 112017014225A2
Authority
BR
Brazil
Prior art keywords
lactobacillus reuteri
lactic acid
strains
composition
acid bacterial
Prior art date
Application number
BR112017014225A
Other languages
English (en)
Inventor
Möllstam Bo
Connolly Eamonn
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of BR112017014225A2 publication Critical patent/BR112017014225A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)

Abstract

a presente invenção refere-se às novas cepas de bactérias do ácido láctico lactobacillus reuteri selecionadas do grupo compreendendo lactobacillus reuteri dsm 32229, lactobacillus reuteri dsm 32230, lactobacillus reuteri dsm 32231 e lactobacillus reuteri dsm 32232 e aos produtos compreendendo estas cepas. a presente invenção refere-se, também, a um uso de uma ou mais cepas de bactérias do ácido láctico como um probiótico para o tratamento de uma inflamação ou infecção, como mastite e/ou candidíase, especialmente após administração tópica de ditas cepas.
BR112017014225A 2015-01-16 2016-01-14 cultura biologicamente pura de lactobacillus reuteri, cepas lactobacillus reuteri, composição de uso de uma ou mais cepas de bactérias do ácido láctico, e da composição, e, método para administração tópica de cepas de bactérias do ácido láctico. BR112017014225A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562104164P 2015-01-16 2015-01-16
PCT/EP2016/050699 WO2016113365A1 (en) 2015-01-16 2016-01-14 Lactic acid bacteria and their use for the treatment of mastitis

Publications (1)

Publication Number Publication Date
BR112017014225A2 true BR112017014225A2 (pt) 2018-03-06

Family

ID=56405271

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014225A BR112017014225A2 (pt) 2015-01-16 2016-01-14 cultura biologicamente pura de lactobacillus reuteri, cepas lactobacillus reuteri, composição de uso de uma ou mais cepas de bactérias do ácido láctico, e da composição, e, método para administração tópica de cepas de bactérias do ácido láctico.

Country Status (12)

Country Link
US (2) US20180273895A1 (pt)
EP (1) EP3244904A1 (pt)
JP (1) JP2018504902A (pt)
KR (1) KR20170103804A (pt)
CN (1) CN107532137A (pt)
AU (1) AU2016208009A1 (pt)
BR (1) BR112017014225A2 (pt)
CA (1) CA2972967A1 (pt)
CL (1) CL2017001818A1 (pt)
HK (1) HK1248756A1 (pt)
MX (1) MX2017007969A (pt)
WO (1) WO2016113365A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700062260A1 (it) * 2017-06-07 2018-12-07 Proge Farm Srl Associazione e composizioni topiche cutanee comprendenti lattobacilli e ossidi metallici e/o semimetallici
CA3123051A1 (en) * 2018-12-19 2020-06-25 Healthy Cow Corporation Ready-to-use probiotic compositions and uses thereof
US20230146454A1 (en) * 2019-09-26 2023-05-11 Precisionbiotics Group Limited Lactobacillus reuteri
WO2022003062A1 (en) * 2020-06-30 2022-01-06 Biogaia Ab Probiotic composition for topical use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955834B2 (en) * 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
EP1997499A1 (en) * 2007-05-31 2008-12-03 Puleva Biotech, S.A. Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
CA2861682C (en) * 2011-12-30 2017-07-25 Abbott Laboratories Concentrated low water activity liquid human milk fortifier including extensively hydrolyzed protein

Also Published As

Publication number Publication date
AU2016208009A1 (en) 2017-07-20
HK1248756A1 (zh) 2018-10-19
US20200318061A1 (en) 2020-10-08
US20180273895A1 (en) 2018-09-27
WO2016113365A1 (en) 2016-07-21
JP2018504902A (ja) 2018-02-22
CN107532137A (zh) 2018-01-02
MX2017007969A (es) 2018-04-10
CA2972967A1 (en) 2016-07-21
KR20170103804A (ko) 2017-09-13
EP3244904A1 (en) 2017-11-22
CL2017001818A1 (es) 2018-03-02

Similar Documents

Publication Publication Date Title
BR112015024330A2 (pt) nova bactéria do ácido láctico, medicamento, alimento ou bebida, e ração que contenham a nova bactéria do ácido láctico
BR112018068593A2 (pt) composições tópicas não aquosas que compreendem uma salicilanilida halogenada
BR112018009192A2 (pt) composição de prebiótico e probiótico combinados
WO2016179440A3 (en) Antimicrobial therapy
CN107208107A8 (zh) 伤口愈合的方法
BR112017027640A2 (pt) leite fermentado inoculado com ambas bactérias ácido-láticas (lab) e bacilo
BR112015026773A2 (pt) cepas bacterianas que têm atividade antimicrobiana e composições de controle biológico que compreendem as mesmas
EA201490512A1 (ru) Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
WO2019066577A3 (ko) 짧은 사슬 지방산 생성 장내 세균 군집의 변화를 이용한 알코올성 간 질환의 진단 및 치료용 조성물
BR112015022833A2 (pt) bactéria de ácido láctico ou um fragmento da mesma, bactéria de ácido láctico isolada ou um fragmento da mesma, uso de bactérias de ácido láctico ou um fragmento das mesmas, composição alimentícia, método para conservação de gêneros alimentícios, e, método de identificação de uma bactéria de ácido láctico
MX2015006681A (es) Formulaciones de vancomicina estabilizadas.
BR112017014225A2 (pt) cultura biologicamente pura de lactobacillus reuteri, cepas lactobacillus reuteri, composição de uso de uma ou mais cepas de bactérias do ácido láctico, e da composição, e, método para administração tópica de cepas de bactérias do ácido láctico.
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
BRPI1011277B8 (pt) produto de bacteriocina lactobacillus pentosus, alimento e composições farmacêuticas contendo o mesmo e uso do mesmo
BR112018003474A2 (pt) bactérias lactobacillus fermentum que reduzem a concentração de acetaldeído
PH12017500708A1 (en) Probiotic and prebiotic compositions
BR112016000901B8 (pt) composições, métodos para a preparação de um produto e produtos alimentícios ou para alimentação animal
JP2017519730A5 (pt)
MX2016016885A (es) Administracion in ovo de cultivos probioticos.
EP4268897A3 (en) Minocycline compounds for biodefense
PH12019502239A1 (en) Lactic acid bacteria, methods and uses thereof
MX2019005535A (es) Streptococcus thermophilus para uso en la preparación de productos fermentados.
BR112021015638A2 (pt) Métodos, composições contendo bactéria produtora de bacileno ou preparações das mesmas
MX2017009247A (es) Un metodo para la activacion de bacterias de acido lactico.
MX2019006086A (es) Uso de una composicion bacteriana para tratar infecciones en las patas de ungulados.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements